Corvus Pharmaceuticals, Inc. (CRVS) Form 8-K — Aug 6, 2026
Corvus Pharmaceuticals reported a second quarter 2026 net loss of $18.0 million, more than double the $8.0 million loss in the year-ago quarter, as research and development expenses roughly doubled to $16.0 million on higher clinical trial costs for soquelitinib. Net loss per share was $0.19 versus $0.10 a year earlier. The company ended June 30, 2026 with $215.2 million in cash, cash equivalents and marketable securities, up from $56.8 million at December 31, 2025, including approximately $189.4 million of net proceeds from a financing completed January 23, 2026. Corvus expects this cash to fund operations into the second quarter of 2028.
Key figures
- Guidance
- Cash, cash equivalents and marketable securities expected to fund operations into the second quarter of 2028
- Total Assets
- 239274000
- Cash Position
- 215228000
- Shares Outstanding
- 92368013
- Cash runway
- into 2Q28
- Cash dec 31 2025
- 56750000
- Q2 2025 net loss
- -7998000
- Q2 2025 rd expense
- 7873000
- Q2 2026 ga expense
- 3333000
- Q2 2026 rd expense
- 15964000
- Q2 2026 stock comp
- 2600000
- Angel pharma round size
- 13500000
- Six month 2025 net income
- 7195000
- Angel pharma carrying value
- 15107000
- Alps trial target enrollment
- 30
- Angel pharma investment made
- 5000000
- Angel pharma ownership stake
- 49%
- Phase3 ptcl target enrollment
- 150
- Jan 2026 financing net proceeds
- 189400000
- Stockholders equity jun 30 2026
- 225328000
- Phase2 atopic dermatitis target enrollment
- 200
Price after filing
Close on the filing date to close N calendar days later (from $13.92). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.